Curated News
By: NewsRamp Editorial Staff
September 08, 2026
OS Therapies to Present at Moody Capital Conference, Advancing Cancer Treatment for Pets
TLDR
- OS Therapies positions OST-HER2 as the go-to for HER2 positive canine cancers, gaining edge in veterinary oncology market.
- OS Therapies, through OS Animal Health, works to re-establish USDA conditional approval for OST-HER2 canine osteosarcoma treatment.
- OS Therapies aims to improve outcomes for pets with cancer, bringing innovative immunotherapies to veterinary oncology.
- OS Therapies presents at Moody Capital Conference, highlighting its focus on HER2 positive cancers in dogs and companion animals.
Impact - Why it Matters
This news matters for pet owners and the veterinary community because it signals progress in the fight against canine cancer. OS Therapies' OST-HER2 could become a groundbreaking treatment for osteosarcoma, a devastating disease in dogs. The company's participation in the Moody Capital conference highlights its growth potential and may attract investment to accelerate development. If successful, OST-HER2 could not only improve and extend the lives of pets but also pave the way for similar immunotherapies in other companion animals and potentially contribute to human cancer research, as HER2-positive cancers are prevalent in both species.
Summary
OS Animal Health, a wholly owned subsidiary of OS Therapies Inc. (NYSE American: OSTX), is making significant strides in veterinary oncology. The company is dedicated to improving outcomes for pets with cancer, focusing on the development and commercialization of OST-HER2, an innovative immunotherapy for canine osteosarcoma. This treatment is being positioned as the "go-to" option for all HER2-positive cancers in dogs and, eventually, for all companion animals. The company is working to re-establish USDA conditional approval, which would allow them to bring this cutting-edge therapy to market.
OS Animal Health is set to present at the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference, an event hosted by Moody Capital Solutions Inc., an independent investment bank with over 40 years of experience. The conference will provide a platform for the company to showcase its advancements and connect with potential investors and partners. Interested parties can register to attend at https://moodycapital.com/conference/. IBN, a multifaceted financial news and publishing company, will be providing comprehensive coverage of the event, with a dedicated portal at https://ibn.fm/MoodyCapital2026Conference that includes summaries and market research tools for all participating companies.
The conference aims to highlight disruptive growth and life sciences companies, and OS Animal Health's participation underscores its commitment to advancing veterinary medicine. With the support of IBN's extensive network, the event will offer significant visibility for OS Therapies and its innovative pipeline. The company's dedication to improving the lives of pets with cancer is a testament to its mission, and this conference serves as a critical step in bringing OST-HER2 to the market, offering hope to pet owners and veterinarians alike.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, OS Therapies to Present at Moody Capital Conference, Advancing Cancer Treatment for Pets
